Recently, accumulating evidence has shown that acquired resistance to chemotherapeutic drugs such as platinum, epidermal growth factor receptor tyramine kinase (EGFR-TK) inhibitors, and anaplastic lymphoma kinase (ALK) inhibitors is associated with increased PD-L1 expression in cancer cells [10–12]. The gene discussed is EGFR; the disease is cancer.